Reversible orofacial dyskinesia after ofloxacin treatment

Area of Science:

• Pharmacology
• Neuroscience
• Clinical Medicine

Background:

• Fluoroquinolone antibiotics are widely used for bacterial infections.
• Orofacial dyskinesia is a rare but serious adverse drug reaction.
• Previous reports link fluoroquinolones to dyskinesia, primarily in specific patient groups.

Observation:

• A patient developed orofacial dyskinesia within three days of initiating ofloxacin therapy.
• The patient's symptoms manifested as involuntary movements of the face and mouth.

Findings:

• This case suggests a potential association between ofloxacin and the development of orofacial dyskinesia.
• The mechanism is hypothesized to involve interference with GABA-ergic neurotransmission.
• The occurrence is rare, particularly outside of elderly patients with compromised organ function or overdose scenarios.

Implications:

• Clinicians should be aware of the potential for orofacial dyskinesia with ofloxacin use.
• Monitoring for neurological side effects is crucial during fluoroquinolone treatment.
• Further research may elucidate the precise mechanisms and risk factors for this adverse event.